Lord's Mark Industries Monitoring Committee Approves ₹200 Crore Rights Issue and ESOP Implementation

2 min read     Updated on 06 Jan 2026, 05:41 PM
scanx
Reviewed by
Jubin VScanX News Team
Overview

Lord's Mark Industries' Fifth Monitoring Committee meeting on January 03, 2026, resulted in unanimous approval of a ₹200 crore rights issue and ESOP plan representing minimum 2% equity capital. The committee reviewed progress on NCLT-ordered capital restructuring, including allotment of 42,65,96,580 shares at 1.25:1 swap ratio, and ratified ₹4,74,170 in monitoring expenses while awaiting BSE trading resumption.

29247066

*this image is generated using AI for illustrative purposes only.

Lord's Mark Industries Limited conducted its Fifth Monitoring Committee meeting on January 03, 2026, through video conferencing under the chairmanship of Erstwhile Resolution Professional Mr. Amit C Poddar. The meeting addressed several critical corporate restructuring matters and strategic initiatives as the company works toward resuming trading on the BSE platform.

Capital Restructuring Progress

The Monitoring Committee reviewed significant progress on implementing the NCLT Order dated July 28, 2025. Key developments in the capital restructuring process include the identification of 4,90,051 equity shares held by former promoters for extinguishment and proportionate reduction of public shareholding to a maximum of 5% per shareholder.

The committee noted approval for a major share allotment as part of the amalgamation process:

Parameter: Details
Share Allotment: 42,65,96,580 equity shares
Face Value: ₹10.00 per share
Swap Ratio: 1.25:1
Beneficiaries: Eligible shareholders of Lord's Mark Industries Pvt. Ltd.
Proposed Record Date: November 21, 2025

The Erstwhile Resolution Professional has maintained constant communication with BSE and SEBI to finalize implementation and resume trading activities.

Rights Issue Approval

The Monitoring Committee unanimously approved a proposal to raise capital through a rights issue, demonstrating strong support for the company's growth plans:

Aspect: Details
Capital Target: Up to ₹200.00 crores
Approval Status: 100% committee support
Timing: Post-resumption of BSE listing and trading
Promoter Rights: Authorized to renounce entitlement to other investors

The rights issue will proceed once the company's shares resume trading on the BSE platform, following completion of all regulatory compliances and capital structure updates.

Employee Stock Option Plan Implementation

To support expansion into renal care and medical technology sectors, the committee approved creation of an Employee Stock Option Plan (ESOP). The company has recently entered the renal care business through acquisition of RenalX Healthcare Systems Limited, which developed an AI-based dialysis machine.

The ESOP structure includes:

Component: Specification
Pool Size: Minimum 2% of equity capital
Base Calculation: 42,65,96,580 existing shares
Purpose: Attract high-caliber professionals
Target Sectors: Renal care and medical technology
Geographic Scope: Domestic and global operations

The company plans to manufacture and sell AI-based dialysis machines, operate dialysis centers across India, and export products internationally. Additionally, the company has developed a remote patient monitoring system with its own data center, receiving significant demand from the United States and Europe.

Financial and Administrative Matters

The committee ratified monitoring period expenses incurred by the Erstwhile Resolution Professional:

Period: November 06, 2025 to January 02, 2026
Total Expenses: ₹4,74,170.00
Primary Components: Professional fees and administrative costs
Approval Status: Unanimously ratified

The expenses primarily comprised the Erstwhile RP's remuneration along with courier charges for various regulatory communications with BSE, SEBI, and the Registrar and Transfer Agent.

The meeting concluded with all agenda items receiving unanimous approval, reflecting strong committee support for the company's strategic direction and regulatory compliance efforts. The company continues working toward full implementation of the NCLT-approved scheme and resumption of trading activities.

like18
dislike

Lord's Mark Industries Limited Submits Pre-Amalgamation Financial Statements as on March 31, 2025

1 min read     Updated on 30 Dec 2025, 09:51 PM
scanx
Reviewed by
Suketu GScanX News Team
Overview

Lord's Mark Industries Limited submitted Pre-Amalgamation Financial Statements as on March 31, 2025 to BSE Limited on December 30, 2025, under Regulation 30 of SEBI listing requirements. The company, formerly known as Lords Mark India Limited and Kratos Energy & Infrastructure Limited, filed these statements for disclosure and record purposes, prepared in accordance with applicable accounting standards and regulatory requirements.

28657308

*this image is generated using AI for illustrative purposes only.

Lord's Mark Industries Limited has submitted its Pre-Amalgamation Financial Statements as on March 31, 2025 to BSE Limited, fulfilling its regulatory obligations under SEBI listing requirements. The submission was made on December 30, 2025, as part of the company's compliance with disclosure norms.

Regulatory Compliance Details

The company filed the financial statements pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These pre-amalgamation statements have been prepared in accordance with applicable accounting standards and regulatory requirements.

Parameter: Details
Filing Date: December 30, 2025
Statement Period: As on March 31, 2025
Regulation: SEBI Regulation 30
BSE Scrip Code: 501261
Purpose: Disclosure and Record

Company Background

Lord's Mark Industries Limited, formerly known as Lords Mark India Limited and Kratos Energy & Infrastructure Limited, operates under BSE scrip code 501261. The company has undergone name changes as part of its corporate evolution.

Filing Purpose and Documentation

The Pre-Amalgamation Financial Statements have been uploaded specifically for disclosure and record purposes. This submission ensures transparency and compliance with stock exchange requirements, providing stakeholders with necessary financial information ahead of any potential amalgamation proceedings.

The filing represents the company's commitment to maintaining regulatory compliance and ensuring proper disclosure of financial information to market participants and regulatory authorities.

like18
dislike
Explore Other Articles